These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538 [TBL] [Abstract][Full Text] [Related]
10. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. De Mattos-Arruda L; Cortes J Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722 [TBL] [Abstract][Full Text] [Related]
11. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401 [TBL] [Abstract][Full Text] [Related]
14. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963 [TBL] [Abstract][Full Text] [Related]
15. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758 [TBL] [Abstract][Full Text] [Related]
17. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Denduluri N; Somerfield MR; Chavez-MacGregor M; Comander AH; Dayao Z; Eisen A; Freedman RA; Gopalakrishnan R; Graff SL; Hassett MJ; King TA; Lyman GH; Maupin GR; Nunes R; Perkins CL; Telli ML; Trudeau ME; Wolff AC; Giordano SH J Clin Oncol; 2021 Feb; 39(6):685-693. PubMed ID: 33079579 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. Yu Q; Zhu Z; Liu Y; Zhang J; Li K PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]